Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 0.76 |
| ▸ | RET | P07949 | 14/20 | 0.76 |
| ▸ | ROS1 | P08922 | 14/20 | 0.76 |
| ▸ | EML4 | Q9HC35 | 12/20 | 0.76 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.76 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.76 |
| ▸ | PLK4 | O00444 | 1/20 | 0.76 |
| ▸ | CIT | O14578 | 1/20 | 0.76 |
| ▸ | AURKA | O14965 | 1/20 | 0.76 |
| ▸ | GAK | O14976 | 1/20 | 0.76 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.76 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.76 |
| ▸ | BUB1 | O43683 | 1/20 | 0.76 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.76 |
| ▸ | STK16 | O75716 | 1/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.76 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.76 |
| ▸ | LATS1 | O95835 | 1/20 | 0.76 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gilteritinib SCHEMBL29355822 | 0.86 | FLT3 (1.00) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL282229 | 0.86 | FLT3 (1.00) | FLT3RETROS1EML4ALK | |
| Gilteritinib SCHEMBL29432551 | 0.86 | FLT3 (1.00) | FLT3RETROS1EML4ALK | |
| SCHEMBL25562040 | 0.86 | FLT3 (0.81) | FLT3RETROS1EML4ALK | |
| SCHEMBL25562519 | 0.86 | FLT3 (0.76) | FLT3RETROS1EML4ALK | |
| SCHEMBL25562493 | 0.85 | FLT3 (0.75) | FLT3RETROS1EML4ALK | |
| SCHEMBL25562513 | 0.85 | FLT3 (0.77) | FLT3RETROS1EML4ALK | |
| SCHEMBL25562542 | 0.85 | FLT3 (0.77) | FLT3RETROS1EML4ALK | |
| SCHEMBL25562512 | 0.85 | FLT3 (0.77) | FLT3RETROS1EML4ALK | |
| SCHEMBL25562540 | 0.85 | FLT3 (0.77) | FLT3RETROS1EML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938132-B2 | Stable pharmaceutical composition for oral administration | ASTELLAS PHARMA INC. (JP) | 2024-03-26 | — | — | US | claimed |
| WO-2025245059-A1 | COMPOSITIONS COMPRISING GSK-3 AND/OR BETA-CATENIN INHIBITORS AND/OR DEGRADERS AND METHODS OF USE THEREOF | YALE UNIVERSITY (US) | 2025-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938132-B2 | Stable pharmaceutical composition for oral administration | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC20A1, RCC1 | FLT3 2633/4885RET 3013/4885ROS1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.